AstroPix: Investigating the Potential of Silicon Pixel Sensors in the Future of Gamma-ray Astrophysics

This paper details preliminary photon measurements with the monolithic silicon detector ATLASPix, a pixel detector built and optimized for the CERN experiment ATLAS. The goal of this paper is to determine the promise of pixelated silicon in future space-based gamma-ray experiments. With this goal in mind, radioactive photon sources were used to determine the energy resolution and detector response of ATLASPix; these are novel measurements for ATLASPix, a detector built for a ground-based particle accelerator. As part of this project a new iteration of monolithic Si pixels, named AstroPix, have been created based on ATLASPix, and the eventual goal is to further optimize AstroPix for gamma-ray detection by constructing a prototype Compton telescope.The energy resolution of both the digital and analog output of ATLASPix is the focus of this paper, as it is a critical metric for Compton telescopes. It was found that with the analog output of the detector, the energyresolution of a single pixel was 7.69 +/- 0.13% at 5.89 keV and 7.27 +/- 1.18% at 30.1 keV, which exceeds the conservative baseline requirements of 10% resolution at 60 keV and is an encouraging start to an optimistic goal of<2% resolution at 60 keV. The digital output of the entire detector consistently yielded energy resolutions that exceeded 100% for different sources. The analog output of the monolithic silicon pixels indicates that thisis a promising technology for future gamma-ray missions, while the analysis of the digital output points to the need for a redesign of future photon-sensitive monolithic silicon pixel detectors.Comment: 12 pages, proceedings, International Society for Optics and Photonics (SPIE) Astronomical Telescopes and Instrumentation Digital Forum, Dec. 14-18 202

AstroPix: novel monolithic active pixel silicon sensors for future gamma-ray telescopes

Space-based gamma-ray telescopes such as the Fermi Large Area Telescope have used single sided silicon strip detectors to track secondary charged particles produced by primary gamma-rays with high resolution. At the lower energies targeted by keV-MeV telescopes, two dimensional position information within a single detector is required for event reconstruction - especially in the Compton regime. This work describes the development of monolithic CMOS active pixel silicon sensors - AstroPix - as a novel technology for use in future gamma-ray telescopes. Based upon sensors (ATLASPix) designed for use in the ATLAS detector at the Large Hadron Collider, AstroPix has the potential to maintain high performance while reducing noise with low power consumption. This is achieved with the dual detection and readout capabilities in each CMOS pixel. The status of AstroPix development and testing, as well as outlook for future testing and application, will be presented

AstroPix: CMOS pixels in space

Space-based gamma-ray telescopes such as the Fermi Large Area Telescope have used single sided silicon strip detectors to measure the position of charged particles produced by incident gamma rays with high resolution. At energies in the Compton regime and below, two dimensional position information within a single detector is required. Double sided silicon strip detectors are one option; however, this technology is difficult to fabricate and large arrays are susceptible to noise. This work outlines the development and implementation of monolithic CMOS active pixel silicon sensors, AstroPix, for use in future gamma-ray telescopes. Based upon detectors designed using the HVCMOS process at the Karlsruhe Institute of Technology, AstroPix has the potential to maintain the high energy and angular resolution required of a medium-energy gamma- ray telescope while reducing noise with the dual detection-and-readout capabilities of a CMOS chip. The status of AstroPix development and testing as well as outlook for application in future telescopes is presented

Changes in persistent contaminant concentration and CYP1A1 protein expression in biopsy samples from northern bottlenose whales, Hyperoodon ampullatus, following the onset of nearby oil and gas development

Author Posting. © Elsevier B.V., 2007. This is the author's version of the work. It is posted here by permission of Elsevier B.V. for personal use, not for redistribution. The definitive version was published in Environmental Pollution 152 (2008): 205-216, doi:10.1016/j.envpol.2007.05.027.A small population of endangered northern bottlenose whales (Hyperoodon ampullatus) inhabits “The Gully” Marine Protected Area on the Scotian Shelf, eastern Canada. Amid concerns regarding nearby oil and gas development, we took 36 skin and blubber biopsy samples in 1996-97 (prior to major development) and 2002-03 (five years after development began), and 3 samples from a population in the Davis Strait, Labrador in 2003. These were analysed for cytochrome P4501A1 (CYP1A1) protein expression (n=36), and for persistent contaminants (n=23). CYP1A1 showed generally low expression in whales from The Gully, but higher levels during 2003, potentially co-incident with recorded oil spills, and higher levels in Davis Strait whales. A range of PCB congeners and organochlorine compounds were detected, with concentrations similar to other North Atlantic odontocetes. Concentrations were higher in whales from The Gully than from the Davis Strait, with significant increases in 4,4’-DDE and trans-nonachlor in 2002-03 relative to 1996-97.Research was funded by the Natural Sciences and Engineering Research Council (NSERC) of Canada, World Wildlife Fund Canada Endangered Species Recovery Fund, Fisheries and Oceans Canada, the National Geographic Society, the Canadian Federation of Humane Societies and two U.K. Royal Society International Collaborative Awards. S.K.H. was supported by a Canadian Commonwealth Scholarship and Royal Society Dorothy Hodgkin Research Fellowship. C.D.M. was awarded a Discovery grant from the Natural Sciences and Engineering Research Council (NSERC) of Canada. J.Y.W was supported by an NSERC PGS B fellowship and the Woods Hole Oceanographic Institution

The All-sky Medium Energy Gamma-ray Observatory eXplorer (AMEGO-X) Mission Concept

The All-sky Medium Energy Gamma-ray Observatory eXplorer (AMEGO-X) is designed to identify and characterize gamma rays from extreme explosions and accelerators. The main science themes include: supermassive black holes and their connections to neutrinos and cosmic rays; binary neutron star mergers and the relativistic jets they produce; cosmic ray particle acceleration sources including Galactic supernovae; and continuous monitoring of other astrophysical events and sources over the full sky in this important energy range. AMEGO-X will probe the medium energy gamma-ray band using a single instrument with sensitivity up to an order of magnitude greater than previous telescopes in the energy range 100 keV to 1 GeV that can be only realized in space. During its three-year baseline mission, AMEGO-X will observe nearly the entire sky every two orbits, building up a sensitive all-sky map of gamma-ray sources and emission. AMEGO-X was submitted in the recent 2021 NASA MIDEX Announcement of Opportunity.Comment: 23 pages, 16 figures, Published Journal of Astronomical Telescopes, Instruments, and System

ATR suppresses telomere fragility and recombination but is dispensable for elongation of short telomeres by telomerase

ATR recognizes critically short telomeres as fragile sites and protects them from chromosomal fusions

All-sky Medium Energy Gamma-ray Observatory: Exploring the Extreme Multimessenger Universe

The All-sky Medium Energy Gamma-ray Observatory (AMEGO) is a probe class mission concept that will provide essential contributions to multimessenger astrophysics in the late 2020s and beyond. AMEGO combines high sensitivity in the 200 keV to 10 GeV energy range with a wide field of view, good spectral resolution, and polarization sensitivity. Therefore, AMEGO is key in the study of multimessenger astrophysical objects that have unique signatures in the gamma-ray regime, such as neutron star mergers, supernovae, and flaring active galactic nuclei. The order-of-magnitude improvement compared to previous MeV missions also enables discoveries of a wide range of phenomena whose energy output peaks in the relatively unexplored medium-energy gamma-ray band

Gestión del tiempo en alumnado universitario con diferentes niveles de rendimiento académico

Resumen En este trabajo se estudia la relación entre gestión del tiempo y rendimiento académico en el alumnado universitario. La hipótesis de partida es que los estudiantes con alto nivel de habilidades en gestión del tiempo obtienen mejores resultados de aprendizaje. Se ha utilizado una muestra de 494 estudiantes universitarios de primer año, en dos universidades colombianas. A esta muestra se administró una adaptación al español del Time Management Behavior Questionnaire (TMBQ), y se recogieron datos sobre las calificaciones académicas en su primer año en la universidad. De manera complementaria, se han celebrado cuatro grupos focales con alumnado de bajo y alto nivel de rendimiento, accediendo a sus experiencias, opiniones y valoraciones en relación con la gestión del tiempo. Los resultados obtenidos indican la existencia de una cierta relación positiva entre las dos variables analizadas, en línea con los hallazgos de estudios previos. Al comparar la gestión del tiempo entre subgrupos de estudiantes que alcanzan las mejores y peores calificaciones, se observan diferencias a favor de los primeros, particularmente en la sub-escala relativa a sus percepciones sobre el control del tiempo. Los discursos de grupo reflejan también mejores conductas autorregulatorias en el manejo del tiempo por parte del alumnado de alto nivel de rendimiento. De acuerdo con estos resultados, se hacen recomendaciones sobre el entrenamiento del alumnado universitario de primer año en estrategias para la gestión del tiempo

Prevalence and architecture of de novo mutations in developmental disorders.

The genomes of individuals with severe, undiagnosed developmental disorders are enriched in damaging de novo mutations (DNMs) in developmentally important genes. Here we have sequenced the exomes of 4,293 families containing individuals with developmental disorders, and meta-analysed these data with data from another 3,287 individuals with similar disorders. We show that the most important factors influencing the diagnostic yield of DNMs are the sex of the affected individual, the relatedness of their parents, whether close relatives are affected and the parental ages. We identified 94 genes enriched in damaging DNMs, including 14 that previously lacked compelling evidence of involvement in developmental disorders. We have also characterized the phenotypic diversity among these disorders. We estimate that 42% of our cohort carry pathogenic DNMs in coding sequences; approximately half of these DNMs disrupt gene function and the remainder result in altered protein function. We estimate that developmental disorders caused by DNMs have an average prevalence of 1 in 213 to 1 in 448 births, depending on parental age. Given current global demographics, this equates to almost 400,000 children born per year

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial